Valneva Shares Rise on Positive Data from Lyme Disease Vaccine Study

Shares in Valneva VLA 5.81%increase; green up pointing triangle rose after the French biotech company reported positive final data from a mid-stage study of a Lyme disease vaccine candidate it is developing with Pfizer.

Valneva said that antibody levels remained well above baseline across all six Lyme disease serotypes and all age groups in the trial. This was six months after participants received the third yearly booster dose of the vaccine candidate under development, called VLA15.